In this issue:
Clinical features associated with COVID outcome in MM
Serum BCMA level normalisation predicts OS in MM patients starting treatment
Renal responses with Kd vs. Vd in relapsed/refractory MM
Autologous HSCT for MM in elderly patients
Postinduction ixazomib maintenance for new, transplant-ineligible MM
Venetoclax added to bortezomib/dexamethasone in relapsed/refractory MM
Adding selinexor to bortezomib/dexamethasone in MM
DRd vs. standard regimens in transplant-ineligible MM
Chromosomal abnormalities and progression from MGUS/smouldering MM to new/relapsed MM
VTd ±daratumumab for transplant-eligible, new MM
Please login below to download this issue (PDF)